Geographic Market Expansion
Coronary Artery Disease
CommercialActive
Key Facts
About Translumina
Translumina is a privately held, commercial-stage medical device company specializing in interventional cardiology products. With a global manufacturing footprint and a portfolio centered on drug-eluting stents and balloons, the company has established a significant presence, particularly in India and other emerging markets. Its strategy combines in-house R&D with strategic acquisitions, such as Blue Medical Devices, to expand its technology portfolio and geographic reach. The company is positioned in the large and growing cardiovascular devices market, competing on quality, innovation, and cost-effectiveness.
View full company profileTherapeutic Areas
Other Coronary Artery Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| MUTI™ Drug‑Eluting Stent | Meril | Commercial |
| Coronary Artery Bypass Grafts | Vascudyne | Pre-clinical |
| Premier DES | Relisys Medical Devices | Commercial |
| Release R DES | Relisys Medical Devices | Commercial |
| Pristine DES | Relisys Medical Devices | Commercial |
| BioMatrix family (Flex/Alpha) | Biosensors International | Commercial |
| Coronary Artery Disease Program | Elixir Medical | Pre-clinical |
| Essential pro Stent | iVascularU | Post-Market |
| FGF-1 | Zhittya Genesis Medicine | Phase 2 |
| OMT-28 | OMEICOS Therapeutics | Phase 2 |
| Fantom Encore | REVA Medical | Commercial |
| Next-Gen Drug-Eluting Stents | Translumina | Development |